Latest Conference Articles

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

Jordan Feld, MD, MPH, explains how HBsAg testing, NUC therapy, and monitoring capacity will shape access to hepatitis B functional cure.

Senu Apewokin, MD, explains why C diff in ICU and chemotherapy patients may reflect colonization, not hospital transmission.

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.

Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.

At ASN Kidney Week 2026, experts said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis C cases.

Aditi Ramakrishnan, MD, MSc, explains how pharmacy benefit gaps and prior authorization denials keep patients from long-acting injectable PrEP.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few patients.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.

Karolinska Institutet’s Antoine Créon, MD, discusses why CKD alerts did not improve screening, retesting, or diagnosis in Stockholm primary care.

Sparsentan cut proteinuria about 70% and kept kidney function stable over 2 years in newly diagnosed IgA nephropathy in the SPARTAN study.

Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.

ASN Kidney Week 2026 experts discussed GLP-1 RAs alongside lifestyle care, global access, and bariatric surgery for obesity in chronic kidney disease.

The US has curative HCV treatment and rapid tests but lags peer nations in prevention for people who inject drugs.

Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.

Naima T. Joseph, MD, MPH, explains measles risks in pregnancy, atypical presentations, and the narrow window for prophylaxis.

Universal HCV testing in pregnancy, DAA therapy, and earlier infant RNA testing can curb mother-to-child hepatitis C transmission.

Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.

Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.

Leon W. Herndon Jr, MD, explains how disease severity, medication adherence, and pressure spikes shape surgical planning.

Ambient AI and analytics may ease clinical workloads and uncover insights, but safety, validated data, HIPAA compliance, and equity must guide adoption.

Immediate DAA treatment, syringe services, and society advocacy are key to eliminating the hepatitis C virus (HCV) among people who use drugs.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.